Prot #54767414MMY2002: An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are

Project: Research project

Project Details

Effective start/end date10/10/1310/10/16


  • Janssen Research & Development, LLC (Prot #54767414MMY2002)